# Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

> **NCT07431307** · PHASE2 · NOT_YET_RECRUITING · sponsor: **BioVersys AG** · enrollment: 120 (estimated)

## Conditions studied

- Ventilator Associated Bacterial Pneumonia (VABP)
- Hospital Acquired Bacterial Pneumonia (HABP)
- Blood Stream Infection
- Meningitis, Bacterial
- Ventriculitis, Infectious

## Interventions

- **DRUG:** BV100 with 50 mg polymyxin B plus ceftazidime/avibactam
- **DRUG:** BV100 with 50 mg polymyxin B plus cefiderocol
- **DRUG:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT07431307
- **Lead sponsor:** BioVersys AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-03
- **Final completion:** 2028-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431307, "Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07431307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*